News Home

Does Amicus Therapeutics, Inc. (FOLD) Have What it Takes to be in Your Portfolio Thursday?

Thursday, August 18, 2022 10:47 AM | InvestorsObserver Analysts

Mentioned in this article

Does Amicus Therapeutics, Inc. (FOLD) Have What it Takes to be in Your Portfolio Thursday?

The 72 rating InvestorsObserver gives to Amicus Therapeutics, Inc. (FOLD) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 83 percent of stocks in the Biotechnology industry, FOLD’s 72 overall rating means the stock scores better than 72 percent of all stocks.

Overall Score - 72
FOLD has an Overall Score of 72. Find out what this means to you and get the rest of the rankings on FOLD!

What do These Ratings Mean?

Finding the best stocks can be tricky. It isn’t easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObserver’s tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.
This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

What's Happening With Amicus Therapeutics, Inc. Stock Today?

Amicus Therapeutics, Inc. (FOLD) stock is lower by -0.83% while the S&P 500 is up 0.06% as of 10:47 AM on Thursday, Aug 18. FOLD is down -$0.10 from the previous closing price of $12.03 on volume of 254,823 shares. Over the past year the S&P 500 is down -2.81% while FOLD is up 16.96%. FOLD lost -$0.99 per share the over the last 12 months. Click Here to get the full Stock Report for Amicus Therapeutics, Inc. stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App